These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 30001317)

  • 1. Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.
    Berry SL; Hameed H; Thomason A; Maciej-Hulme ML; Saif Abou-Akkada S; Horrocks P; Price HP
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006639. PubMed ID: 30001317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of NanoLuc, RedLuc and Luc2 as bioluminescent reporters in a cutaneous leishmaniasis model.
    Agostino VS; Trinconi CM; Galuppo MK; Price H; Uliana SRB
    Acta Trop; 2020 Jun; 206():105444. PubMed ID: 32173317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An axenic amastigote system for drug screening.
    Callahan HL; Portal AC; Devereaux R; Grogl M
    Antimicrob Agents Chemother; 1997 Apr; 41(4):818-22. PubMed ID: 9087496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
    De Rycker M; Hallyburton I; Thomas J; Campbell L; Wyllie S; Joshi D; Cameron S; Gilbert IH; Wyatt PG; Frearson JA; Fairlamb AH; Gray DW
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2913-22. PubMed ID: 23571538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.
    Aulner N; Danckaert A; Rouault-Hardoin E; Desrivot J; Helynck O; Commere PH; Munier-Lehmann H; Späth GF; Shorte SL; Milon G; Prina E
    PLoS Negl Trop Dis; 2013; 7(4):e2154. PubMed ID: 23593521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds.
    Ravinder ; Bhaskar ; Gangwar S; Goyal N
    Curr Microbiol; 2012 Dec; 65(6):696-700. PubMed ID: 22945482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit.
    De Muylder G; Ang KK; Chen S; Arkin MR; Engel JC; McKerrow JH
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1253. PubMed ID: 21811648
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Tadele M; Abay SM; Makonnen E; Hailu A
    Drug Des Devel Ther; 2020; 14():1307-1317. PubMed ID: 32280200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileishmanial activities and mechanisms of action of indole-based azoles.
    Pagniez F; Abdala-Valencia H; Marchand P; Le Borgne M; Le Baut G; Robert-Piessard S; Le Pape P
    J Enzyme Inhib Med Chem; 2006 Jun; 21(3):277-83. PubMed ID: 16918075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species.
    Tavares GSV; Mendonça DVC; Lage DP; Granato JDT; Ottoni FM; Ludolf F; Chávez-Fumagalli MA; Duarte MC; Tavares CAP; Alves RJ; Coimbra ES; Coelho EAF
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):236-246. PubMed ID: 29481714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.
    Lamotte S; Aulner N; Späth GF; Prina E
    Sci Rep; 2019 Jan; 9(1):438. PubMed ID: 30679614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of synthetic tetrahydroindeno[2,1-c]quinolines on Leishmania mexicana.
    Hernández-Chinea C; Carbajo E; Sojo F; Arvelo F; Kouznetsov VV; Romero-Bohórquez AR; Romero PJ
    Parasitol Int; 2015 Dec; 64(6):479-83. PubMed ID: 26148815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.
    Sereno D; Roy G; Lemesre JL; Papadopoulou B; Ouellette M
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1168-73. PubMed ID: 11257031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of the anti-leishmanial activity and toxicity of PK11195.
    Guedes CES; Dias BRS; Petersen ALOA; Cruz KP; Almeida NJ; Andrade DR; Menezes JPB; Borges VM; Veras PST
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(4):e170345. PubMed ID: 29412342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on Leishmania amazonensis.
    Stroppa PHF; Antinarelli LMR; Carmo AML; Gameiro J; Coimbra ES; da Silva AD
    Bioorg Med Chem; 2017 Jun; 25(12):3034-3045. PubMed ID: 28433512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eugenia piauhiensis Vellaff. essential oil and γ-elemene its major constituent exhibit antileishmanial activity, promoting cell membrane damage and in vitro immunomodulation.
    Nunes TAL; Costa LH; De Sousa JMS; De Souza VMR; Rodrigues RRL; Val MDCA; Pereira ACTDC; Ferreira GP; Da Silva MV; Da Costa JMAR; Véras LMC; Diniz RC; Rodrigues KADF
    Chem Biol Interact; 2021 Apr; 339():109429. PubMed ID: 33713644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
    Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
    Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.
    García-García V; Oldfield E; Benaim G
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6386-9. PubMed ID: 27458218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.